NetworkNewsBreaks – Pressure BioSciences Inc.’
Post# of 1354
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide biotechnology and other industries, today announced the successful application of its Ultra Shear Technology(TM) (“UST(TM)”) platform. According to the update, the novel UST platform was used for the development of more potent formulations of wide-ranging nutraceuticals of high therapeutic value, allowing for more controlled dosing and opportunities for lower cost solutions for both manufacturers and consumers. Specifically, PBI reported breakthrough results in processing one of the most powerful antioxidants known to science, astaxanthin (“AsX”), in extremely fine and uniform, monodisperse nanoemulsions of oil in water. These results are critically important for fast and efficient absorption by the water-based biochemistry of humans and animals. “Nanoemulsions produced by PBI’s UST platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter*,” said Gary B. Smejkal, senior research scientist at PBI, explaining the breakthrough achieved by the company. “Because these particles are so small, they do not scatter light and thus appear as clear ruby red liquids that disperse freely in water or other clear beverages. The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer